Posts tagged “Pozen”
With a sales force already dedicated to selling an osteoarthritis drug, Horizon Pharma is better suited to selling Pozen's pain drug Vimovo. Read more about how Pozen benefits from the deal.
The key to the deal for Pozen is guaranteed minimum royalty payments for Vimovo, an osteo-arthritis drug, the Chapel Hill-based company says.
After landing Sanofi as a drug partner to commercialize its cardiovascular drug, Pozen is now pursuing a drug partner in cancer. Read why Pozen believes cancer is the next best opportunity for the company.
Is Pozen-AstraZeneca partnership unraveling? Firms amend sales-challenged arthritis drug Vimovo deal
Chapel-Hill based Pozen and AstraZeneca have amended their agreement on osteo-arthritis drug Vimovo, paving the way for what could be an unraveling of a drug partnership dating to 2006. Sales have disappointed both firms.
Early-stage startups seeking money weren't the only companies taking the stage at CED's Tech Venture Conference. WRALTechWire Insiders can read all about six companies that have grown from upstarts to stalwarts in their respective sectors. Will Bronto, Netsertive, Overture, ReverbNation, StrikeIron and WebAssign someday go the IPO route?
Pozen believes that Sanofi is the best possible big pharma partner to sell its 'safer on the stomach' aspirin. Read how this drug will fits in Sanofi's drug portfolio.
While Pozen works on landing a drug partner to market its prospective new heart drug, it's now starting to look like Pozen might need global partners. Read more about the company's status.
AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?
Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?
The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?
Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.